This was a randomized, open‐label, controlled phase II clinical trial to investigate the safety, efficacy, and outcomes of intrarenal artery infusion of autologous peripheral‐blood‐derived CD34+ cells for patients with chronic kidney disease (CKD; ie, stage III or IV).

中文翻译：

---

慢性肾病患者肾内动脉自体CD34 +细胞输注的安全性和有效性：一项随机，开放标签，受控的II期临床试验。

这是一项随机，开放标签，对照的II期临床试验，旨在研究自体外周血源CD34 +细胞对慢性肾脏病（CKD；即III期或IV）。